Paul Avillach

Paul Avillach

Auto-generated profile, based on publicly available information

Paul Avillach

Affiliation Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, United States of America

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2023 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MGMichael A Gargano
Michael A Gargano
NMNicolas Matentzoglu
Nicolas Matentzoglu
BCBen Coleman
Ben Coleman
EAEunice B Addo-Lartey
Eunice B Addo-Lartey
AAAnna V Anagnostopoulos
Anna V Anagnostopoulos
PRPeter N. Robinson
Peter N. Robinson
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.

19 August 2020 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
GBGabriel A. Brat
Gabriel A. Brat
GWGriffin M. Weber
Griffin M. Weber
NGNils Gehlenborg
Nils Gehlenborg
PAPaul Avillach
Paul Avillach
NPNathan P. Palmer
Nathan P. Palmer
IKIsaac S. Kohane
Isaac S. Kohane
We leveraged the largely untapped resource of electronic health record data to address critical clinical and epidemiological questions about Coronavirus Disease 2019 (COVID-19). To do this, we formed an international consortium (4CE) of 96 hospitals across five countries (www.covidclinical.net). Contributors utilized the Informatics for Integrating Biology and the Bedside (i2b2) or Observational Medical Outcomes Partnership (OMOP) platforms to map to a common data model. The group focused on temporal changes in key laboratory test values. Harmonized data were analyzed locally and converted to a shared aggregate form for rapid analysis and visualization of regional differences and global commonalities. Data covered 27,584 COVID-19 cases with 187,802 laboratory tests. Case counts and laboratory trajectories were concordant with existing literature. Laboratory tests at the time of diagnosis showed hospital-level differences equivalent to country-level variation across the consortium partners. Despite the limitations of decentralized data generation, we established a framework to capture the trajectory of COVID-19 disease in patients and their response to interventions.

23 September 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JSJan Stefan Sanders
Jan Stefan Sanders
MSMustafa Sahin
Mustafa Sahin
JHJoseph Hostyk
Joseph Hostyk
ATAudrey Thurm
Audrey Thurm
SJSebastien Jacquemont
Sebastien Jacquemont
CBCarrie E. Bearden
Carrie E. Bearden

10 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YLYuan Luo
Yuan Luo
AEAlal Eran
Alal Eran
NPNathan Palmer
Nathan Palmer
PAPaul Avillach
Paul Avillach
ALAmi Levy-Moonshine
Ami Levy-Moonshine
IKIsaac S. Kohane
Isaac S. Kohane

1 September 2021 in JAMA Pediatrics
Verified
Journal Article
Closed access
PDF file
AFAliya G. Feroe
Aliya G. Feroe
NUNishant Uppal
Nishant Uppal
AGAlba Gutiérrez-Sacristán
Alba Gutiérrez-Sacristán
SMSajad Mousavi
Sajad Mousavi
PGPhilip Greenspun
Philip Greenspun
PAPaul Avillach
Paul Avillach
In 2016, approximately 1.9% (1 in 54) of US children 8 years of age were diagnosed with autism spectrum disorder (ASD),1 and the prevalence has increased since then. That growth has spurred more expansive efforts to understand not only the prevalence of the disease but also its comorbidities and corresponding pharmacological treatments.1,2

29 May 2018 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
QZQiu-Yue Zhong
Qiu-Yue Zhong
BKBeth W Karlson
Beth W Karlson
BGBizu Gelaye
Bizu Gelaye
SFSean Finan
Sean Finan
PAPaul Avillach
Paul Avillach
MWMichelle A. Williams
Michelle A. Williams
We examined the comparative performance of structured, diagnostic codes vs. natural language processing (NLP) of unstructured text for screening suicidal behavior among pregnant women in electronic medical records (EMRs). Women aged 10–64 years with at least one diagnostic code related to pregnancy or delivery (N = 275,843) from Partners HealthCare were included as our “datamart.” Diagnostic codes related to suicidal behavior were applied to the datamart to screen women for suicidal behavior. Among women without any diagnostic codes related to suicidal behavior (n = 273,410), 5880 women were randomly sampled, of whom 1120 had at least one mention of terms related to suicidal behavior in clinical notes. NLP was then used to process clinical notes for the 1120 women. Chart reviews were performed for subsamples of women. Using diagnostic codes, 196 pregnant women were screened positive for suicidal behavior, among whom 149 (76%) had confirmed suicidal behavior by chart review. Using NLP among those without diagnostic codes, 486 pregnant women were screened positive for suicidal behavior, among whom 146 (30%) had confirmed suicidal behavior by chart review. The use of NLP substantially improves the sensitivity of screening suicidal behavior in EMRs. However, the prevalence of confirmed suicidal behavior was lower among women who did not have diagnostic codes for suicidal behavior but screened positive by NLP. NLP should be used together with diagnostic codes for future EMR-based phenotyping studies for suicidal behavior.